查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1439069

人工子宮設施市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按技術、按應用、最終用戶、地區和競爭細分

Artificial Womb Facility Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Technology, By Application, By End user, By Region and Competition
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2022 年，全球人工子宮設施市場價值為 2.7132 億美元，預計在預測期內將出現令人印象深刻的成長，到 2028 年CAGR為 7.25%。全球人工子宮設施市場正處於轉型的邊緣。隨著醫療技術的進步以及人們對替代懷孕方法的興趣日益濃厚，人造子宮不再只是科幻小說中的概念，而是現實。這項突破性的創新有望徹底改變懷孕和分娩，為家庭、醫療保健提供者和研究人員提供大量機會。人造子宮，也稱為體外發育室，是一種複製自然子宮條件以支持胎兒在體外生長和發育的裝置。它的目的是提供一個受控的環境，使早產或有風險的胎兒可以繼續發育，直到達到可存活的階段，從而有可能減少與早產相關的併發症。這些設備有助於緩解與傳統懷孕相關的各種醫療和倫理挑戰。

市場概況
預測期 2024-2028
2022 年市場規模 27132萬美元
2028 年市場規模 40999萬美元
2023-2028 年CAGR 7.25%
成長最快的細分市場 新生兒護理
最大的市場 北美洲

全球醫療保健產業正在見證快速的技術進步。這些創新超越了疾病治療的範圍，並擴展到生殖健康和產前護理領域。早產是一個重大的全球健康問題，大約 10% 的出生是早產。人工子宮技術旨在提供一種解決方案，使早產兒在受控環境中持續發育。人造子宮引發了關於體外懷孕的倫理影響的討論。市場將繼續受到這些道德討論和監管決策的影響。人工子宮可以為與不孕症作鬥爭的個人和夫婦帶來希望，提供傳統懷孕的替代方案。

主要市場促進因素

孕產婦死亡率的降低正在推動全球人工子宮設施市場

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：全球人工子宮設施市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按技術（生物反應器、支援設備中的外部裝置、其他）
    • 按應用（產前護理、新生兒護理）
    • 依最終用戶（超級專科醫院、研究中心、體外受精中心 (IVF)）
    • 按地區
    • 按公司分類 (2022)
  • 市場地圖
    • 依技術
    • 按應用
    • 按最終用戶
    • 按地區

第 5 章：亞太地區人工子宮設施市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 6 章：歐洲人工子宮設施市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 歐洲：國家分析
    • 法國
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美人工子宮設施市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 北美：國家分析
    • 美國
    • 墨西哥
    • 加拿大

第 8 章：南美洲人工子宮設施市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • 南美洲：國家分析
    • 巴西
    • 阿根廷
    • 哥倫比亞

第 9 章：中東和非洲人工子宮設施市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 依技術
    • 按應用
    • 按最終用戶
    • 按國家/地區
  • MEA：國家分析
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：市場動態

  • 促進要素
  • 挑戰

第 11 章：市場趨勢與發展

  • 最近的發展
  • 產品發布
  • 併購

第 12 章：全球人工子宮設施市場：SWOT 分析

第 13 章：波特的五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 客戶的力量
  • 替代產品的威脅

第14章：競爭格局

  • American University of Beirut (AUB)
  • Biotex Inc.
  • California Preterm Birth Initiative
  • Emmaus Life Sciences, Inc.
  • Hebrew University
  • Institute of Life Sciences
  • Juno Perinatal Healthcare
  • Sera Prognostics, Inc.
  • Shanghai First Maternity and Infant Hospital
  • SomaGenics Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 21704

Global Artificial Womb Facility Market was valued at USD 271.32 Million in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 7.25% through 2028. The Global Artificial Womb Facility Market is on the brink of transformation. With advancements in medical technology and a growing interest in alternative methods of gestation, the artificial womb is no longer just a concept from science fiction but a reality. This groundbreaking innovation promises to revolutionize pregnancy and childbirth, offering a multitude of opportunities for families, healthcare providers, and researchers. An artificial womb, also known as an ectogenesis chamber, is a device that replicates the conditions of a natural womb to support the growth and development of a fetus outside of a human body. It aims to provide a controlled environment where a preterm or at-risk fetus can continue to develop until it reaches a viable stage, potentially reducing the complications associated with premature births. These devices can be instrumental in alleviating various medical and ethical challenges associated with traditional pregnancies.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 271.32 Million
Market Size 2028USD 409.99 Million
CAGR 2023-20287.25%
Fastest Growing SegmentNeonatal Care
Largest MarketNorth America

The global healthcare industry is witnessing rapid technological advancements. These innovations extend beyond the treatment of diseases to the realm of reproductive health and prenatal care. Preterm birth is a significant global health issue, with approximately 10% of all births occurring prematurely. Artificial womb technology aims to provide a solution by enabling the continued development of preterm babies in a controlled environment. Artificial wombs open up discussions about the ethical implications of gestation outside the human body. The market will continue to be shaped by these ethical discussions and regulatory decisions. Artificial wombs could offer hope to individuals and couples struggling with infertility, providing an alternative to traditional pregnancy.

Key Market Drivers

Reduction in Maternal Mortality is Driving the Global Artificial Womb Facility Market

Maternal mortality, a tragic and largely preventable occurrence, has long been a global concern. The World Health Organization (WHO) defines maternal mortality as the death of a woman during pregnancy, childbirth, or within 42 days of termination of pregnancy, irrespective of the duration and site of the pregnancy. While significant progress has been made in reducing maternal mortality rates worldwide, it continues to be a critical issue, particularly in developing countries. As we strive for better healthcare outcomes, one innovative solution is emerging as a potential game-changer: the artificial womb facility. This technology has the potential to significantly reduce maternal mortality and drive the global artificial womb facility market. Maternal mortality is a multifaceted problem that reflects not only the health of women but also the accessibility and quality of healthcare services. The root causes of maternal mortality are varied and complex, including inadequate prenatal care, limited access to healthcare facilities, cultural and social factors, and medical complications during pregnancy and childbirth. According to the WHO, approximately 810 women die every day from preventable causes related to pregnancy and childbirth. This equates to over 295,000 maternal deaths annually. Artificial wombs, often referred to as "ectogenesis," are a groundbreaking technological development in the field of reproductive medicine. These devices aim to provide an environment outside the human body where a developing fetus can thrive. While still in the experimental stage, artificial wombs hold the promise of transforming reproductive healthcare by reducing the risks associated with pregnancy and childbirth. One of the most significant advantages of artificial wombs is the potential to eliminate many of the risks that pregnant women face during the gestational period. Maternal mortality often results from complications related to pregnancy, including preeclampsia, hemorrhage, infections, and obstructed labor. With artificial wombs, the fetus can be safely nurtured outside the mother's body, reducing the risk of these life-threatening complications.

In many parts of the world, particularly in remote or underserved regions, access to proper medical facilities and trained healthcare professionals is limited. Artificial womb facilities could be set up in centralized locations, making specialized prenatal care and monitoring more accessible to a broader population. This has the potential to reduce maternal mortality by providing timely interventions and monitoring, thus ensuring safer pregnancies and childbirth. Artificial womb technology also offers an alternative to traditional pregnancies. Women who face health issues or complications during pregnancy may have more options to consider, including transferring their pregnancy to an artificial womb. This can empower women to make choices that prioritize their well-being and the health of their child while reducing the risk of maternal mortality. As research and development in artificial womb technology advances, private and public investments in this field are growing. The global artificial womb facility market is expected to experience substantial growth in the coming years as more resources are allocated to develop and refine this technology.

Rising Preterm Birth Rates is Driving the Global Artificial Womb Facility Market

Preterm birth is a major global health challenge. According to the World Health Organization (WHO), approximately 15 million babies are born prematurely each year, accounting for over 1 in 10 births worldwide. Preterm birth is a leading cause of infant mortality and is associated with a higher risk of lifelong health issues, such as cognitive and developmental impairments, respiratory problems, and more. The rise in preterm birth rates is a matter of concern for healthcare systems worldwide. Several factors contribute to the increase in preterm births. Older mothers (above the age of 35) and very young mothers (under the age of 18) are at higher risk of preterm births. Women carrying twins, triplets, or more are more likely to experience preterm labor and delivery. Smoking, substance abuse, and poor prenatal care can increase the risk of preterm birth. Conditions like high blood pressure and diabetes can increase the likelihood of preterm delivery. Exposure to pollution and other environmental hazards can also play a role.

As preterm birth rates continue to rise, medical professionals are exploring innovative ways to mitigate the associated risks and complications. Artificial womb facilities, also known as extrauterine support systems, represent a promising solution. These facilities are designed to provide an environment that mimics the conditions of the mother's womb, allowing the premature infant to continue developing and growing outside the mother's body.

Artificial womb facilities enable continuous monitoring of vital signs and fetal development, providing early intervention if complications arise. These facilities can potentially reduce the risks of infections and complications associated with traditional neonatal intensive care units (NICUs). Artificial womb technology aims to provide an environment that supports better development of organs and tissues, reducing long-term health issues for premature babies. Infant Bonding: Parents can participate more actively in the care of their premature infants as they can see and interact with them in a controlled environment.

Key Market Challenges

Ethical and Moral Concerns

The ethical and moral concerns surrounding artificial wombs are significant and complex. Questions about when life begins, the potential for misuse, and the creation of a dystopian society where human reproduction is entirely divorced from natural processes have raised red flags among many stakeholders. Striking a balance between technological progress and ethical considerations is a daunting task that the market must confront.

Regulatory Hurdles

The regulatory framework for artificial womb technology is far from clear. Existing laws and regulations governing human reproduction and medical devices are not well-suited to address the unique challenges presented by artificial wombs. As such, market players are faced with the challenging task of navigating an intricate web of regulations, potentially slowing down the development and implementation of this technology.

Technical Complexity

Developing an artificial womb is an immensely complex technological feat. Researchers and engineers must replicate the intricate processes of fetal development, including oxygen and nutrient exchange, waste removal, and hormonal signaling. Achieving this level of sophistication requires extensive research and development, pushing the limits of our current understanding of biology, robotics, and material science.

Safety and Health Concerns

Ensuring the safety and health of both the fetus and the mother in an artificial womb is of paramount importance. Any technical failure or oversight could lead to disastrous consequences. There are challenges in creating artificial environments that can mimic the womb's natural conditions, regulate various physiological processes, and respond to the evolving needs of a developing fetus. Additionally, there are concerns about the long-term health and psychological well-being of children gestated in artificial wombs.

Cost and Accessibility

The cost of developing and maintaining artificial womb facilities is considerable. This expense may limit access to this technology, creating disparities in reproductive healthcare. Ensuring equitable access for all individuals who may benefit from artificial wombs is a challenge that needs to be addressed in a fair and inclusive manner.

Social and Psychological Implications

The introduction of artificial wombs may have profound social and psychological implications. Questions about the role of traditional pregnancy and its cultural significance, the potential for increased societal pressure on women to use artificial wombs, and the effect on parent-child bonding are all issues that need careful consideration.

Public Perception and Acceptance

The public's acceptance and perception of artificial womb technology is a vital factor in its success. Market players need to engage in open and transparent communication to educate the public about the potential benefits and risks of this technology, and to gain the trust and support of society.

Key Market Trends

Technological Advancements

Technological advancements have played a pivotal role in transforming various aspects of our lives. In recent years, these advancements have extended their reach into the field of healthcare and, specifically, artificial womb technology. The development and adoption of artificial womb facilities are on the rise, driven by increasing technological innovations, which have the potential to revolutionize the way we care for premature babies and address various reproductive health challenges. The progress in biotechnology has led to significant breakthroughs in artificial womb technology. Biocompatible materials, improved incubation systems, and better understanding of fetal development have made it possible to create an environment that closely mimics the mother's womb. Artificial placenta systems have been developed to provide the necessary oxygen and nutrients to the developing fetus, effectively bypassing the need for a natural placenta. This breakthrough technology is a game-changer for the care of premature infants. Technological advancements have allowed for the miniaturization of components, making artificial womb facilities more compact and efficient. This portability can potentially enable care for premature infants in various healthcare settings.

Segmental Insights

Application Insights

Based on the category of Application, Neonatal Care emerged as the dominant player in the global market for Artificial Womb Facility in 2022. Proton Pump Inhibitors are a class of drugs that reduce the production of stomach acid by blocking the proton pump, which is responsible for the secretion of gastric acid in the stomach lining. Proton Pump Inhibitors have shown exceptional efficacy in reducing stomach acid, making them highly effective in treating peptic ulcers and related conditions. They help in the healing of ulcers and provide relief from the symptoms, including heartburn and indigestion. Proton Pump Inhibitors are generally well-tolerated and have fewer side effects compared to other classes of drugs used in peptic ulcer treatment. This has contributed to their widespread acceptance among patients. Proton Pump Inhibitors are available in various formulations, including oral capsules, tablets, and even intravenous options for more severe cases. This versatility in administration makes them suitable for a wide range of patients. In many countries, Proton Pump Inhibitors are available over the counter, making them easily accessible to patients without a prescription. This convenience further boosts their dominance in the market. Proton Pump Inhibitors are cost-effective both for patients and healthcare systems, making them an attractive option for long-term ulcer management and prevention.

End user Insights

The In-Vitro Fertilization Centers (IVF) segment is projected to experience rapid growth during the forecast period IVF is a well-established method to produce high-quality embryos. During an IVF cycle, eggs and sperm are combined in a controlled environment, and the resulting embryos are assessed for their health and genetic quality. These superior embryos are ideal candidates for transfer to artificial wombs, as they have a higher chance of successful development. Currently, gestational surrogacy is the primary alternative for individuals and couples who cannot carry a pregnancy. However, IVF eliminates the need for gestational surrogates in many cases. Instead, embryos can be transferred to an artificial womb, reducing ethical, legal, and emotional complexities associated with surrogacy arrangements. IVF centers serve as hubs for research and development in the field of assisted reproductive technologies. These facilities are often affiliated with research institutions and universities, which provides a unique advantage for artificial womb technology research. The shared knowledge and expertise accelerate progress in this field.

Regional Insights

North America emerged as the dominant player in the global Artificial Womb Facility market in 2022, holding the largest market share in terms of value. North America is home to a robust ecosystem of research institutions, universities, and companies dedicated to advancing medical technology. This environment fosters cutting-edge research and development activities in the field of artificial womb technology. From prestigious institutions like the Massachusetts Institute of Technology (MIT) to leading healthcare corporations, the region has the resources and expertise to spearhead advancements in artificial womb facilities. The United States and Canada maintain regulatory frameworks that support innovation and the development of medical technologies. This fosters an environment in which researchers and companies can more easily navigate the complexities of bringing new medical devices, such as artificial womb facilities, to market. The Food and Drug Administration (FDA) in the United States, for instance, has been receptive to approving these technologies when they meet safety and efficacy standards.

Key Market Players

American University of Beirut (AUB)

Biotex Inc.

California Preterm Birth Initiative

Emmaus Life Sciences, Inc.

Hebrew University

Institute of Life Sciences

Juno Perinatal Healthcare

Sera Prognostics, Inc.

Shanghai First Maternity and Infant Hospital

SomaGenics Inc.

Report Scope:

In this report, the Global Artificial Womb Facility Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Artificial Womb Facility Market, By Technology:

  • Bioreactors
  • Extrauter in Support Devices
  • Others

Artificial Womb Facility Market, By Disease Indication:

  • Prenatal Care
  • Neonatal Care

Artificial Womb Facility Market, By End user:

  • Super Specialty Hospitals
  • Research Centers
  • In-Vitro Fertilization Centers (IVF)

Artificial Womb Facility Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Artificial Womb Facility Market.

Available Customizations:

  • Global Artificial Womb Facility market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Artificial Womb Facility Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Technology (Bioreactors, Extrauter in Support Devices, Others)
    • 4.2.2. By Application (Prenatal Care, Neonatal Care)
    • 4.2.3. By End user (Super Specialty Hospitals, Research Centers, In-Vitro Fertilization Centers (IVF))
    • 4.2.4. By Region
    • 4.2.5. By Company (2022)
  • 4.3. Market Map
    • 4.3.1. By Technology
    • 4.3.2. By Application
    • 4.3.3. By End user
    • 4.3.4. By Region

5. Asia Pacific Artificial Womb Facility Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology
    • 5.2.2. By Application
    • 5.2.3. By End user
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Artificial Womb Facility Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Technology
        • 5.3.1.2.2. By Application
        • 5.3.1.2.3. By End user
    • 5.3.2. India Artificial Womb Facility Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Technology
        • 5.3.2.2.2. By Application
        • 5.3.2.2.3. By End user
    • 5.3.3. Australia Artificial Womb Facility Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Technology
        • 5.3.3.2.2. By Application
        • 5.3.3.2.3. By End user
    • 5.3.4. Japan Artificial Womb Facility Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Technology
        • 5.3.4.2.2. By Application
        • 5.3.4.2.3. By End user
    • 5.3.5. South Korea Artificial Womb Facility Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Technology
        • 5.3.5.2.2. By Application
        • 5.3.5.2.3. By End user

6. Europe Artificial Womb Facility Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Application
    • 6.2.3. By End user
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Artificial Womb Facility Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End user
    • 6.3.2. Germany Artificial Womb Facility Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End user
    • 6.3.3. Spain Artificial Womb Facility Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End user
    • 6.3.4. Italy Artificial Womb Facility Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Technology
        • 6.3.4.2.2. By Application
        • 6.3.4.2.3. By End user
    • 6.3.5. United Kingdom Artificial Womb Facility Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Technology
        • 6.3.5.2.2. By Application
        • 6.3.5.2.3. By End user

7. North America Artificial Womb Facility Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Application
    • 7.2.3. By End user
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Artificial Womb Facility Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End user
    • 7.3.2. Mexico Artificial Womb Facility Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End user
    • 7.3.3. Canada Artificial Womb Facility Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End user

8. South America Artificial Womb Facility Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By End user
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Artificial Womb Facility Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End user
    • 8.3.2. Argentina Artificial Womb Facility Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End user
    • 8.3.3. Colombia Artificial Womb Facility Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End user

9. Middle East and Africa Artificial Womb Facility Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Application
    • 9.2.3. By End user
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Artificial Womb Facility Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End user
    • 9.3.2. Saudi Arabia Artificial Womb Facility Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End user
    • 9.3.3. UAE Artificial Womb Facility Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End user

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Artificial Womb Facility Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product

14. Competitive Landscape

  • 14.1. American University of Beirut (AUB)
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Product & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Biotex Inc.
  • 14.3. California Preterm Birth Initiative
  • 14.4. Emmaus Life Sciences, Inc.
  • 14.5. Hebrew University
  • 14.6. Institute of Life Sciences
  • 14.7. Juno Perinatal Healthcare
  • 14.8. Sera Prognostics, Inc.
  • 14.9. Shanghai First Maternity and Infant Hospital
  • 14.10. SomaGenics Inc.

15. Strategic Recommendations

16. About Us & Disclaimer